A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy, Safety, and Tolerability of LP352 in the Treatment of Seizures in Children and Adults with Developmental and Epileptic Encephalopathies

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516412-17-00

Acronym

LP352-301

Enrollment

102

Registered

2025-06-11

Start date

2025-08-26

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Developmental and Epileptic Encephalopathies (DEE)

Brief summary

Frequency percent change in countable motor seizures during Maintenance compared to Baseline

Detailed description

1.• 50% responder rate (the percentage of participants with a ≥50% reduction in countable motor seizures) during Maintenance compared to Baseline• Frequency percent change in countable motor seizures during Treatment compared to Baseline

Interventions

DRUGBexicaserin

DRUGLP352 (bexicaserin) Placebo Oral Solution

Eligibility

Sex/Gender

All

Age

0 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Frequency percent change in countable motor seizures during Maintenance compared to Baseline	—

Secondary

Measure	Time frame
1.• 50% responder rate (the percentage of participants with a ≥50% reduction in countable motor seizures) during Maintenance compared to Baseline• Frequency percent change in countable motor seizures during Treatment compared to Baseline	—

Countries

Belgium, France, Germany, Italy, Latvia, Netherlands, Portugal, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026